Announced
Completed
Financials
Sources
Tags
Pharmaceuticals
Spain
biopharma
Acquisition
Cross Border
Majority
Private
Completed
Single Bidder
Friendly
Private Equity
Synopsis
WACKER, a German multinational chemical company, completed the acquisition of ADL BioPharma, a pharmaceutical company, from Kartesia, a private equity firm, for €100m. “Acquiring ADL BioPharma is an important step in the continued growth of our biotechnology business, with which we expect to generate one billion euros in sales in 2030. Development at ADL BioPharma has been very good in recent years, and their sales have grown considerably. The additional fermentation capacities will provide a foundation for growth in the field of sustainably produced dietary ingredients. WACKER’s technological expertise combined with the capacities of ADL BioPharma will make us a much stronger player on this growth market,” Christian Hartel, WACKER CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.